Gerrit Los
Affiliations: | University of California, San Diego, La Jolla, CA |
Area:
Molecular Biology, Cell Biology, OncologyGoogle:
"Gerrit Los"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Murray J, Thomas H, Berry P, et al. (2014) Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer. 110: 1977-84 |
| Young MPD, Sherk C, Bleam M, et al. (2014) Abstract LB-236: Preclinical efficacy of targeting FGF autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230 Cancer Research. 74 |
| Bellovin DI, Palencia S, Hestir K, et al. (2014) Abstract 5449: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC Cancer Research. 74: 5449-5449 |
| Gemo AT, Deshpande AM, Palencia S, et al. (2014) Abstract 5446: FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification Cancer Research. 74: 5446-5446 |
| Deshpande AM, Palencia S, Bellovin DI, et al. (2014) Abstract 2845: Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody Cancer Research. 74: 2845-2845 |
| Fang DD, Cao J, Jani JP, et al. (2013) Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line. Frontiers of Medicine. 7: 462-76 |
| Ihnen M, zu Eulenburg C, Kolarova T, et al. (2013) Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Molecular Cancer Therapeutics. 12: 1002-15 |
| Kuruma H, Matsumoto H, Shiota M, et al. (2013) A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Molecular Cancer Therapeutics. 12: 567-76 |
| Michaud NR, Jani JP, Hillerman S, et al. (2012) Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621. Mabs. 4: 710-23 |
| Zhu Z, Shi M, Hu W, et al. (2012) Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding. Bmc Genomics. 13: 355 |